Recently, immune checkpoint inhibitors (ICIs), such as programmed death-1 receptor (PD-1)/programmed death ligand-1 (PD-L1), have been implicated in many solid tumors, including malignant melanoma and non-small cell lung cancer (NSCLC), and have achieved good therapeutic effects [3, 4]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.